AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 NOV 13 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Immunization with a vaccine containing mouse fibroblasts transfected with DNA from B16 mouse melanoma cells that expressed syngeneic and allogeneic major histocompatibility complex (MHC) class I determinants significantly increased survival in mice with malignant melanoma.
"Most neoplasms do not induce antitumor immune responses that can control tumor growth," explained Edward De Zoeten and colleagues at the University of Illinois in Chicago. "Tumor associated antigens (TAAs) are insufficiently immunogenic. We hypothesized that the immunogenic properties of 'weak' TAAs formed by the neoplasm would be enhanced if they were expressed by highly antigenic cells."
The investigators transfected highly antigenic allogeneic mouse fibroblasts (LM; H-2[superscript]k) with B16 mouse melanoma DNA and used the fibroblasts to immunize C57BL/6 mice that were syngeneic with the melanoma (H-2[superscript]k). The treated mice survived longer than did untreated control mice.
When mice received transfected cells that expressed allogeneic MHC class I determinants, the antimelanoma immune response was enhanced (An optimum anti-melanoma response in mice immunized with fibroblasts transfected with DNA from mouse melanoma cells requires the expression of both ...
Source: HighBeam Research, Vaccine effective against melanoma in mice.